Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’

Meta Platforms
Eli Lilly and Company
T. Rowe Price Group, Inc.
Vistra Corp.

Meta Platforms

META

0.00

Eli Lilly and Company

LLY

0.00

T. Rowe Price Group, Inc.

TROW

0.00

Vistra Corp.

VST

0.00

On CNBC’s “Halftime Report Final Trades,” Bill Baruch, founder and CIO of both Blue Line Capital, an investment advisor, and Blue Creek Capital Management, named Eli Lilly and Company (NYSE:LLY) as his final trade.

Supporting his view, Citigroup analyst Geoff Meacham, on Wednesday, maintained Eli Lilly with a Buy and increased the price target from $1,500 to $1,600.

Rob Sechan, CEO of NewEdge Wealth, picked Vistra Corp. (NYSE:VST).

Lending support to his choice, Scotiabank analyst Andrew Weisel, on Wednesday, maintained Vistra with a Sector Outperform and raised the price target from $293 to $298.

Don’t forget to check out our premarket coverage here

Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, recommended Meta Platforms, Inc. (NASDAQ:META).

Meta Platforms will release second-quarter financial results after the closing bell on Wednesday, July 29. Analysts expect the company to report quarterly earnings at $7.20 per share on revenue of $60.24 billion.

Joseph M. Terranova, senior managing director for Virtus Investment Partners, named T. Rowe Price Group, Inc. (NASDAQ:TROW) as his final trade.

Barclays analyst Benjamin Budish, on Tuesday, maintained T. Rowe Price Group with an Underweight rating and raised the price target from $89 to $108.

Price Action:

  • T. Rowe Price shares rose 2.2% to close at $118.58 on Wednesday.
  • Vistra shares gained 1.1% to settle at $160.23 during the session.
  • Meta shares gained 3.1% to close at $681.31 on Wednesday.
  • Eli Lilly shares rose 0.4% to settle at $1,156.63 during the session.

Photo via Shutterstock